Global Recombinant Human Growth Hormone (RHGH) Market, By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, and Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, and Other Pharmacy) – Industry Trends and Forecast to 2031.
Recombinant Human Growth Hormone (RHGH) Market Analysis and Size
The recombinant human growth hormone (RHGH) market is experiencing significant growth globally, driven by several key factors. One of the primary drivers is the increasing prevalence of growth hormone deficiency (GHD) and other growth disorders, which is creating a growing demand for RHGH therapies. In addition, the development of long-acting formulations of RHGH is improving patient compliance and convenience, further driving market growth. Increased healthcare spending, especially in developing countries, is improving patients' access to RHGH therapies. Moreover, the exploration of RHGH therapies for new indications, such as improving muscle mass in the elderly or enhancing athletic performance, is opening up new market opportunities.
The global recombinant human growth hormone (RHGH) market size was valued at USD 1.61 billion in 2023 and is projected to reach USD 3.53 billion by 2031, with a CAGR of 10.30% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016 - 2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, and Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, and Other Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
SottoPelle (U.S.), Novartis AG (Switzerland), Orion Pharma AB (Sweden), Full Life Wellness Center (U.S.), BioTE Medical, LLC (U.S.), Merck KGaA (Germany), Pfizer Inc. (U.S.), TherapeuticsMD, Inc. (U.S.), Papillon Medical (Canda), United Pharmacy (U.S.), Noven Pharmaceuticals, Inc. (U.S.), GEA Group Aktiengesellschaft (Germany), Novo Nordisk A/S (Denmark), GeneScience Pharmaceuticals Co., Ltd. (China), Actiza Pharmaceutical Private Limited (India), Defy Medical (U.S.), Neuva Aesthetics (U.S.), ZRT Laboratory (U.S.), Bayer AG (Germany), and Allergan (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Recombinant Human Growth Hormone (RHGH) is a synthetic form of the human growth hormone (HGH), which is naturally produced by the pituitary gland in the brain. RHGH is produced using recombinant DNA technology, where the gene for human growth hormone is inserted into host cells, such as bacteria or yeast, which then produce the hormone. RHGH is used therapeutically to treat growth hormone deficiency (GHD) in children and adults, and other conditions.
Recombinant Human Growth Hormone (RHGH) Market Dynamics
Drivers
- Growing Prevalence of Growth Disorders
The rising incidence of growth disorders, including growth hormone deficiency (GHD) and Turner syndrome, can significantly impact an individual's quality of life, leading to physical and developmental challenges. With increasing awareness of these disorders and improving diagnostic techniques, more patients are being identified and seeking treatment. This is expected to continue driving the demand for RHGH therapies, especially as the global population ages and the prevalence of these disorders rises, driving the market growth.
- Development of Long-Acting Formulations
The development of long-acting formulations of RHGH therapies has the potential to revolutionize the market by improving patient compliance and convenience. Currently, frequent recombinant human growth hormone injections are required, which can be cumbersome for patients and may lead to non-compliance. Long-acting formulations offer the advantage of fewer injections, reducing the treatment burden for patients. This could lead to better treatment outcomes and increased patient satisfaction, ultimately driving market growth. As research in this area continues and more long-acting formulations become available, the market for RHGH therapies is expected to expand significantly, catering to a larger patient population.
Opportunities
- RHGH Therapies for New Indications
The exploration of recombinant human growth hormone therapy for new indications beyond traditional uses in addition to treating growth disorders, such as growth hormone deficiency (GHD) and Turner syndrome, RHGH therapies are being investigated for their potential to improve muscle mass in the elderly and enhance athletic performance. These new indications are based on the role of growth hormone in promoting muscle growth and repair. As research in this area progresses and new applications are discovered, the market for RHGH therapies is expected to expand, catering to a broader range of patients and needs.
- Rising Healthcare Expenditure
Rising healthcare costs, particularly in developing countries, are significantly improving access to recombinant human growth hormone (RHGH) therapies for patients. As economies develop and healthcare systems expand, there is a greater focus on addressing the healthcare needs of the population, including the treatment of growth disorders. This increased spending is enabling more patients to afford RHGH therapies, thereby driving market growth. In addition, as healthcare infrastructure improves and awareness about growth disorders increases, the demand for RHGH therapies is expected to rise further, supported by the growing healthcare budgets in these regions.
Restraints/Challenges
- High Cost of Treatment
Factors such as dosage, administration frequency, and treatment duration result in changing recombinant human growth hormone costs. In many developing countries, the high cost of these therapies places them out of reach for a large portion of the population. In addition, even in developed countries with robust healthcare systems, patients without adequate insurance coverage may struggle to afford these treatments. As a result, the high cost of RHGH therapies can limit access to these potentially life-changing treatments for many individuals.
- Safety Concerns Regarding RHGH
Surgeries While RHGH therapies are generally considered safe and effective when used appropriately, there are potential risks associated with their use. The disadvantages of recombinant human growth hormone include the development of diabetes, increased intracranial pressure, and potential long-term effects on growth and development. Safety concerns can cause both patients and healthcare providers to hesitate in using RHGH therapies, particularly in cases where the benefits may not outweigh the risks and can be a major challenge for market growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In August 2023, the FDA approved Opko Health, Inc. and Pfizer's once-weekly somatrogon for children with a growth hormone deficiency, showcasing the strategic advancements of key players in the market. This long-acting injectable, Somatrogon-ghla (Ngenla), has demonstrated noninferiority to somatropin in improving annual height velocity, as evidenced by phase 3 trial data
- In May 2023, Novo Nordisk made significant progress in the human growth hormone therapy market with a positive recommendation from the European Medicines Agency for once-weekly Sogroya in children aged three and above, targeting growth hormone deficiency and development failure in adolescents. This positions Sogroya as a promising replacement therapy, marking a significant milestone in Novo Nordisk's strategic expansion efforts
Recombinant Human Growth Hormone (RHGH) Market Scope
The market is segmented on the basis of application, route of administration, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Growth hormone deficiency
- Turner syndrome
- Idiopathic short stature
- Prader Willi syndrome
- Others
Route of administration
- Intravenous
- Intramuscular
- Subcutaneous
- Oral
End use
- Hospital pharmacy
- Retail pharmacy
- Clinics
- Other pharmacy
Recombinant Human Growth Hormone (RHGH) Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, application, route of administration, and distribution channel as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America is expected to dominate the market due to growing geriatric population, the presence of established market leaders, and ongoing research aimed at developing innovative recombinant human growth hormone therapies.
Asia-Pacific is expected to witness significant growth during the forecast period due to factors such as population expansion and heightened awareness among the populace regarding healthcare. Furthermore, the economic landscape of the continent has improved, leading to advancements in healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Recombinant Human Growth Hormone (RHGH) Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- SottoPelle (U.S.)
- Novartis AG (Switzerland)
- Orion Pharma AB (Sweden)
- Full Life Wellness Center (U.S.)
- BioTE Medical, LLC (U.S.)
- Merck KGaA (Germany)
- Pfizer Inc. (U.S.)
- TherapeuticsMD, Inc. (U.S.)
- Papillon Medical (Canada)
- United Pharmacy (U.S.)
- Noven Pharmaceuticals, Inc. (U.S.)
- GEA Group Aktiengesellschaft (Germany)
- Novo Nordisk A/S (Denmark)
- GeneScience Pharmaceuticals Co., Ltd. (China)
- Actiza Pharmaceutical Private Limited (India)
- Defy Medical (U.S.)
- Neuva Aesthetics (U.S.)
- ZRT Laboratory (U.S.)
- Bayer AG (Germany)
- Allergan (Ireland)
SKU-